trending Market Intelligence /marketintelligence/en/news-insights/trending/siK2LY8A2XUlk0YlXWvi8Q2 content esgSubNav
In This List

West Pharmaceutical Q3 profit climbs 3.3% YOY; full-year outlook raised

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


West Pharmaceutical Q3 profit climbs 3.3% YOY; full-year outlook raised

West Pharmaceutical Services Inc. said its third-quarter earnings rose 3.3% year over year and raised its outlook for 2019.

The Exton, Pa.-based company reported adjusted net income of $59.5 million, or 79 cents per share, a gain from $57.6 million, or 76 cents per share, in the prior-year period.

The S&P Global Market Intelligence consensus normalized EPS estimate for the quarter was 71 cents.

Net sales rose 5.7% year over year to $456.1 million from $431.7 million. Meanwhile, research and development expenses fell 7.9% from the prior-year period to $9.3 million from $10.1 million.

On a GAAP basis, net income grew from the prior-year period to $56.3 million, or 75 cents per share, from $55.2 million, or 73 cents per share.

For the first nine months of 2019, the company's adjusted net income totaled $182.5 million, or $2.42 per share, a 16.2% yearly increase from $157.1 million, or $2.08 per share, in the year-ago period.

Net sales for the nine months ended Sept. 30 increased 5.7% year over year to $1.37 billion from $1.29 billion.

GAAP net income for the same period grew 14.8% year over year to $177.8 million, or $2.36 per share, from $154.9 million, or $2.05 per share.

The company raised its full-year outlook, and now expects adjusted EPS in the range of $3.10 to $3.15 for the full year, from its previous guidance in the range of $3.00 to $3.10.

West Pharmaceutical also expects net sales at between $1.82 billion to $1.83 billion for the full year. The company previously estimated net sales to reach the range of $1.81 billion to $1.83 billion.

The S&P Global Market Intelligence consensus normalized EPS estimate for the full year is $3.06.